Innovative Diagnostics Resolution Bioscience specializes in next-generation liquid biopsy cancer diagnostics, offering physicians minimally invasive tools to guide targeted therapies and monitor treatment efficacy, which presents opportunities to expand clinical partnerships and grow institutional adoption.

Growth through Partnerships The company has established collaborations with leading organizations such as Mirati Therapeutics and LabCorp, demonstrating a strong network in cancer diagnostics; leveraging these relationships could facilitate deployment of new tests and increase market penetration.

Recent Acquisition Widely acquired by Agilent Technologies in 2021 and now part of Exact Sciences, Resolution Bioscience’s integration into larger corporate structures offers a strategic foundation for expanding sales channels and accessing broader customer bases within the oncology testing landscape.

Regulatory Milestones Achieving Breakthrough Device Designation from the FDA highlights the company’s innovative edge and FDA recognition, which can accelerate trust and adoption among healthcare providers and facilitate entry into new clinical markets.

Market Potential With a revenue range of up to $10 million and ongoing development of companion diagnostics, Resolution Bioscience is positioned to scale its offerings; sales strategies should focus on highlighting its cutting-edge molecular analytics platform and expanding the reach of its clinical tests to academic, hospital, and commercial labs.